Syros Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 0/6
Syros Pharmaceuticals has a total shareholder equity of $-11.1M and total debt of $41.1M, which brings its debt-to-equity ratio to -369.3%. Its total assets and total liabilities are $85.0M and $96.1M respectively.
Key information
-369.3%
Debt to equity ratio
US$41.08m
Debt
| Interest coverage ratio | n/a |
| Cash | US$58.28m |
| Equity | -US$11.12m |
| Total liabilities | US$96.12m |
| Total assets | US$85.00m |
Recent financial health updates
Recent updates
Syros Pharmaceuticals: Entering A Decisive Era With An Expected 2024 Phase 3 Readout
Jul 02Syros Pharmaceuticals: Rising Despite Dilution, A Must Look
Jan 14Syros Pharmaceuticals: A Major Vote Of Confidence From Insiders
Sep 20Syros gets FDA orphan drug designation for pancreatic cancer treatment SY-5609
Sep 13Syros Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Financial Position Analysis
Short Term Liabilities: SYRS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: SYRS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: SYRS has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: SYRS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SYRS has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: SYRS has less than a year of cash runway if free cash flow continues to reduce at historical rates of 15.6% each year